PlainPill

Venlafaxine

Also known as Effexor

The short answer. Most people who report on Venlafaxine say it did not help (only 22% of 58 positive). It is most often used for mood: 62% of 21 reports say that improved. It is well studied — 314 meta-analyses on PubMed. The most common complaint is withdrawal.

What users report
22%helped58 reports · medium confidence
13 helped19 mixed26 didn't help

From 87 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
314
meta-analyses
562
RCTs
5,238
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Venlafaxine does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 314 meta-analyses on PubMed ↗ · 562 randomized trials ↗

Lancet · 2018 · Meta-analysis / systematic review
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

Conclusion: All antidepressants were more efficacious than placebo in adults with major depressive disorder. Smaller differences between active drugs were found when placebo-controlled trials were included in the analysis, whereas there was more variability in efficacy and acceptability in head-to-head trials. These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants.

PubMed 29477251 ↗
Lancet Psychiatry · 2024 · Meta-analysis / systematic review
Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis

Conclusion: According to the available evidence, the combination of a selective serotonin reuptake inhibitor and a second-generation antipsychotic-and particularly of fluoxetine and olanzapine-could be the optimal treatment choice for psychotic depression. These findings should be taken into account in the development of clinical practice guidelines. However, these conclusions should be interpreted cautiously in view of the low number of included studies and the limitations of these studies.

PubMed 38360024 ↗
Mol Psychiatry · 2023 · Meta-analysis / systematic review
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis

Conclusion: Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment of adults with stable MDD.

PubMed 36253442 ↗
Lancet · 2019 · Meta-analysis / systematic review
Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis

Conclusion: To our knowledge, this is the largest contemporary review of pharmacological agents for the treatment of generalised anxiety disorder by use of network analysis. There are several effective treatment choices for generalised anxiety disorder across classes of medication. The failure of initial pharmacological therapy might not be a reason to abandon a pharmacological treatment strategy.

PubMed 30712879 ↗
Registered clinical trials

272 human trials on ClinicalTrials.gov test Venlafaxine — 184 completed, 18 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

Boxed warning (the FDA's strongest label warning): “Suicidality and antidepressant drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the…”

Full label on DailyMed (NIH) ↗

FDA recalls

28 recalls of products named for Venlafaxine. Most recent:

  • 2025-04-16 · Class II: Presence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet. record ↗
  • 2025-01-29 · Class III: Failed Tablet/Capsule Specifications: Missing tab ID on either side of the tablet record ↗
  • 2024-07-31 · Class II: Failed Dissolution Specifications: Out-of-specification results observed for dissolution testing at the 8-hour and 12-hour pull intervals. record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

131,560 adverse-event reports mention Venlafaxine. Most often reported:

  • Drug ineffective · 9,998
  • Nausea · 9,125
  • Fatigue · 8,203
  • Headache · 7,506
  • Dizziness · 6,591
  • Depression · 6,354

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

US government research funding (NIH)

NIH has funded 11 research projects with Venlafaxine in the title, $7,690,692 in total (1990–2013). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Venlafaxine ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

withdrawal ×10insomnia ×3brain zaps ×2headache ×2emotional blunting ×2libido loss ×2brain fog ×2mania ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“I really got better from anxiety ... on effexor. My personal miracle drug does not work for everyone.”
HelpedRead the discussion ↗
“I tried Venlafaxine and my ADHD improved significantly. However, it also had a certain amount of excitotoxicity, and I couldn't sleep at night.”
MixedRead the discussion ↗
“I started Venlafaxine three months ago when I got depressed again...and it got me out of bed, but NAC was the game changer for me.”
HelpedRead the discussion ↗
“I found that Venlafaxine was good once it down regulated my norephineprine. Before I was constantly full of somatic anxiety but now it’s definitely improved.”
MixedRead the discussion ↗
Read more Venlafaxine reviews →
Top discussions (5)

Other options for mood

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate